Zimmer Biomet Holdings, Inc. (ZBH)

Over the past six months, Zimmer Biomet's stock price has experienced some fluctuations. As of September 30, 2025, the share price was $98.50, representing an 8.24% decline from October 1, 2024, when it was $107.34. The stock's 52-week low was $89.22, and its 52-week high was $114.72. Recent events impacting the stock include the Q2 2025 earnings release on August 7, 2025, the Annual General Meeting on May 29, 2025, the Q1 2025 earnings release on May 5, 2025, analyst ratings, and tariff uncertainty and earnings outlook.

The demand for Zimmer Biomet's products and services can exhibit some seasonality. Elective medical procedures often see increased demand towards the end of the year as patients aim to meet their insurance deductibles or utilize remaining flexible spending account funds. Demand might be slightly lower during summer months due to vacation schedules. The company has reported strong demand for elective medical procedures and recovery in such procedures, contributing to sales growth. The aging global population is also a consistent driver of demand for orthopedic care.

Zimmer Biomet Holdings, Inc. is a global medical technology company focused on musculoskeletal healthcare, designing, manufacturing, and marketing orthopedic reconstructive products, surgical products, and traumatology equipment. The company operates within the Health Technology sector, specifically focusing on Medical Devices, with a mission to alleviate pain and improve the quality of life for people around the world.

Zimmer Biomet has a significant global presence, operating in over 40 countries with approximately 25 production sites worldwide as of the end of 2023. The company's net sales are geographically distributed, with the Americas accounting for 62.5%, Europe/Middle East/Africa for 21.6%, and Asia/Pacific for 15.9%. Its products are marketed through direct sales channels and distributors across these regions.

Zimmer Biomet generally maintains a strong brand reputation, driven by its extensive product portfolio, global distribution network, and focus on innovation. In the past year, product approvals and launches, strategic acquisitions and partnerships, leveraging digital health and robotics, new Chief Medical Advisors, and concerns about GLP-1 drugs have contributed to its reputation.

Zimmer Biomet Holdings, Inc. is a publicly traded company with ownership distributed among institutional investors, individual investors, and company insiders. Institutional shareholders own a significant portion, approximately 97.16% of the company. Zimmer Biomet insiders own 30.84% of the company.